The target blood pressure may be set at a higher level for elderl

The target blood pressure may be set at a higher level for elderly patients with CKD than for buy PD0332991 younger patients with CKD, although there is

insufficient evidence at present to support this. However, tighter blood pressure control is preferable for elderly CKD patients with diabetes or proteinuria, who are at high risk of progression to ESKD and occurrence of CVD, including cerebrovascular disease. Based on these considerations, the above blood pressure targets have been recommended for elderly hypertensive patients with CKD. In elderly hypertensive patients with CKD, great care should be taken to avoid excessive reduction of blood pressure. Some studies of elderly CKD patients have demonstrated a J-curve relationship between the reduction of blood pressure and an increase in all-cause mortality and cerebrovascular morbidity. The lower limit of the target blood pressure range should be set individually for each patient according to his/her general condition, because it is currently difficult to establish the level in an empirical manner. It has been reported that CCBs slow the progression of CKD in elderly patients with CKD. In addition, the efficacy of diuretics and RAS inhibitors in reducing the

incidence of CVD in elderly patients with CKD is supported by accumulating evidence. Therefore, these antihypertensive agents have been recommended as first-line drugs. Bibliography 1. Suzuki H, et al. Clin Oxymatrine Exp Hypertens. 2001;23:189–201. (Level 4)   MK-4827 research buy 2. Beckett NS, et al. N Engl J Med. 2008;358:1887–98. (Level 2)   3. Fagard RH, et al. Arch Intern Med. 2007;167:1884–91. (Level 4)   4. Gueyffier F, et al. Lancet. 1999;353:793–6. (Level 4)   5. Staessen JA, et al. Lancet. 2000;355:865–72. (Level 1)   6. Collaborative Research Group. JAMA. 1991;265:3255–64. (Level 2)   7. Pahor M, et al. Arch Intern Med. 1998;158:1340–5. (Level 2)   8. Sesso R, et al. Nephrology (Carlton).

2008;13:99–103. (Level 4)   9. Young JH, et al. J Am Soc Nephrol. 2002;13:2776–82. (Level 4)   10. Okada T, et al. Hypertens Res. 2009;32:1123–9. (Level 4)   11. Agarwal R. Clin J Am Soc Nephrol. 2009;4:830–7. (Level 4)   12. Hayashi K, et al. Hypertens Res. 2010;33:1211–20. (Level 4)   13. Boutitie F, et al. Ann Intern Med. 2002;136:438–48. (Level 1)   14. Weiner DE, et al. J Am Soc Nephrol. 2007;18:960–6. (Level 4)   15. Denardo SJ, et al. Am J Med. 2010;123:719–26. (Level 4)   16. Somes GW, et al. Arch Intern Med. 1999;159:2004–9. (Level 4)   17. Kostis JB, et al. JAMA. 1997;278:212–6. (Level 4)   18. Meesserli FH, et al. JAMA. 1998;279:1903–7. (Level 1)   19. CUDC-907 in vivo Dahlof B, et al. Lancet. 2002;359:995–1003. (Level 2)   20. Frances CD, et al. Arch Intern Med. 2000;160:2645–50.

(B) As a comparison the Rd KW20 was grown in BHI (■) and CDM (■)

(B) As a comparison the Rd KW20 was grown in BHI (■) and CDM (■) and the adhC mutant was grown in BHI (▲) and CDM (▲ with dotted lines). (C) Rd KW20 (■) and adhC mutant (♦) were then grown with high oxygen until 24 hr when the oxygen tension was changed to low oxygen. To assess whether AdhC was being expressed under these aerobic conditions in the wild type cells we Selleck GF120918 firstly monitored AdhC activity during the growth cycle. The cells were GDC-0449 research buy assayed for AdhC activity (by assay of GSNO reductase activity), at different time points through the growth cycle. Figure 2A shows that AdhC activity increases during exponential phase, and then decreases in late exponential and stationary

phase. RNA was also extracted from H. influenzae wild-type strain at early, mid and late log phase and RT-PCR was performed using 16 S and adhC-estD

primers (Figure 2B). We also investigated the effect of differences in oxygen tension on AdhC expression by growing cultures in low, medium and high oxygen levels; Figure 2C shows that AdhC activity was highest in cells grown at highest oxygen tension and activity decreased as oxygen tension in the culture decreased. Taken together these results indicated that adhC expression in H. influenzae is highest under aerobic conditions and this is associated with glucose metabolism. Figure 2 Change in AdhC specific activity during growth of H. influenzae . (A) Samples were Ibrutinib mouse taken and assayed for AdhC enzyme activity from early log phase (3 hr), mid-log phase (4.5 h), check details log phase (5.5 h) late log phase (8 h) and stationary phase (18 h). (B) RT-PCR for the 16SrDNA (lanes 1–4) and adhC-estD (lanes 5–8) using RNA from the time points 3 h (lanes 1 and 6), 5.5 h (lanes 2 and 7) and 8 h (lanes 3 and 8). Lanes 4 and 5 are representative negative controls. Lane 9 is the ladder. (C) At time points throughout the H. influenzae growth phase AdhC specific activity was measured from cells grown with different oxygen tensions (low tension are the black

bar and high oxygen tension are the grey bars). The enzyme activity is presented as change in NADH consumed per minute per mg total protein. Y-error bars indicate +/− 1 standard deviation of the mean. Units are μmol NADH oxidized min-1 mg protein-1. The growth curves are indicated by the OD600 of cells grown at low oxygen levels (black circle) and high oxygen levels (gray box). (*P < 0.001, **P < 0.002, ***P < 0.0005). AdhC is required for defense against reactive aldehydes To determine whether AdhC had a role in protection against the reactive aldehydes known to be relevant and toxic during aerobic growth, we grew wild-type (Rd KW20) and its isogenic adhC mutant in the presence of some of these compounds and measured the end point of growth (OD600), growth of any culture did not continue beyond the 18 hr point.

The fold has been linked to three different functions in bacteria

The fold has been linked to three different functions in bacteria: oxidoreductase, copper chaperone, or cell division factor. PcoA and CueO perform a particular case of oxidation activity of cuprous ions [35]. CueO is mainly found in Enterobacteria whereas PcoA is characteristic of Pseudomonadales and Xanthomonadales, being the presence of both proteins mutually exclusive. Evolution of copper homeostasis in gamma Pevonedistat chemical structure proteobacteria Diverse biochemical, genetic and crystallographic studies have been performed to characterize the different proteins involved in copper tolerance in gamma proteobacteria [11, 13, 15, 25, 33, 36]. In this paper we analyzed the

current copper homeostasis model, where systems are the evolutionary and functional unit, from a phylogenomic perspective. It can be observed from our results that copper homeostatic systems do not behave as evolutionary units but particular species assemble different combinations of basic functions. To PD0332991 explain this behavior we propose that the process

by which bacteria handle copper can be compared to a metabolic pathway since organisms avoid free copper ions within the cell by developing copper translocation routes based in precise sequences of specific protein-protein interactions [16–18]. There are currently different models aimed at explaining the evolution of metabolic pathways. The patchwork hypothesis postulates that duplication of genes encoding primitive and promiscuous enzymes (capable of P-gp inhibitor catalyzing various reactions) allows each descendant enzyme to specialize in one of the ancestral reactions, this model considers the chemical mechanism as dominant [37]. Alternatively, the retrograde hypothesis suggests that, in the case where a substrate tends to be depleted, gene duplication can provide an enzyme capable of supplying the exhausted substrate, Isotretinoin giving rise to homologous enzymes catalyzing consecutive reactions

with the implicit assumption that substrate specificity is dominant [38]. Assuming that the selectable phenotype would be the control of copper concentration in the cellular space in response to its availability, the fitness value would rely first on the ability of proteins for copper binding (a trait previously and independently acquired) and then on the affinity and specificity of protein-protein interactions. Following these considerations, we propose two alternative hypotheses for the evolution of copper homeostasis in gamma proteobacteria: 1) Function is dominant. 2) Protein-protein interaction is dominant. In the first case and assuming each protein fulfills a specific function among the three known for copper homeostasis proteins in bacteria, its occurrence in a repertoire will be determined by functional complementation and not by stringent protein-protein interactions.

Han HD, Lee A, Song CK, Hwang T, Seong H, Lee CO, Shin BC: In viv

Han HD, Lee A, Song CK, Hwang T, Seong H, Lee CO, Shin BC: In vivo distribution and antitumor activity of heparin-stabilized doxorubicin-loaded liposomes. Int J Pharm 2006, 313:181–188.CrossRef 23. Li X, Hirsh DJ, Cabral-Lilly D, Zirkel A, Gruner SM, Janoff AS, Perkins WR: Doxorubicin physical state in solution and inside liposomes loaded via a pH gradient. Biochim Biophys Acta 1998, 1415:23–40.CrossRef 24. Na K, Lee SA, Jung SH, Hyun J, Shin BC: Elastin-like polypeptide modified liposomes for enhancing cellular uptake

into tumor cells. Colloids Surf B Biointerfaces 2012, 91:130–136.CrossRef Selleck AZD8931 25. Hanzlikova M, Soininen P, Lampela P, Mannisto PT, Raasmaja A: The role of PEI structure and size in the PEI/liposome-mediated synergism of gene transfection. Plasmid 2009, 61:15–21.CrossRef 26. Jung SH, Na K, Lee SA, Cho SH, Seong H, Shin BC: Gd(iii)-DOTA-modified sonosensitive liposomes for ultrasound-triggered release and MR imaging. Nanoscale Res Lett 2012, 7:462–471.CrossRef 27. Hwang T, Han HD, Song CK, Seong H, Kim JH, Chen X, Shin BC: Anticancer drug-phospholipid conjugate for enhancement of intracellular drug delivery. Macromol Symp GW3965 manufacturer 2007, 249–250:109–115.CrossRef 28. Xiong S, Yu B, Wu J, Li H, Lee RJ: Preparation, therapeutic efficacy and intratumoral localization of targeted daunorubicin liposomes

conjugating folate-PEG-CHEMS. Biomed Pharmacother 2011, 65:2–8.CrossRef 29. Kluza E, Yeo SY, Schmid S, van der Schaft DW, Boekhoven RW, Schiffelers RM, Storm G, Strijkers GJ, Nicolay K: Anti-tumor activity of liposomal glucocorticoids: the relevance of liposome-mediated drug delivery, intratumoral localization and systemic activity. J Control Release 2011, 151:10–17.CrossRef Competing interests The authors declare that they have no competing interests. Authors’ contributions YB performed the preparation and characterization of the liposomes. HNJ participated in the intracellular mafosfamide uptake and cell cytotoxicity assay.

HDH and BCS conceived of the study and participated in its design and coordination. All authors read and approved the final manuscript.”
“Background The quaternary Cu2ZnSnS4 (CZTS) compound, derived from CuInS2 by replacing In(III) with Zn(II) and Sn(IV), has the Ro 61-8048 price advantages of optimum direct band gap (around 1.5 eV) for use in single-junction solar cells, abundance of the constituent elements, and high absorption coefficient (>104 cm-1) [1–5]. Thus, increasing attention has been paid on CZTS materials in recent years [6–10]. Low-cost solar cells based on CZTS films as absorber layers have achieved an increasing conversion efficiency [11–15]. CZTS nanocrystalline materials have been found to show potentials for use in negative electrodes for lithium ion batteries [16] and counter electrodes for high-efficiency dye-sensitized solar cells [17–19] and as novel photocatalysts for hydrogen production [20].

Restoring the complete

medium again caused the oxygen con

Restoring the complete

medium again caused the oxygen concentration to fall. The same behavior was observed in a duplicate experiment. These experiments show that oxygen and glucose utilization are interdependent. Heterogeneous patterns of protein SN-38 mw synthetic activity in biofilms The induction of a GFP has been used to reveal regions of active protein synthesis in biofilms [12–14]. When this technique was applied to P. aeruginosa biofilms grown in drip-flow reactors, a stratified pattern of activity was observed (Figure 2). Expression of GFP was localized in a band at the top of the biofilm adjacent to the source of nutrients and oxygen. The dimension of the GFP-expressing zone averaged 66 ± 30 μm (n = 3, ± SD). The average thickness of the entire biofilm was 170 ± 78 μm (n = 3, ± SD) (Table 1). While the predominant zone of activity was along the air interface (Figure 2A), Selleck Lazertinib GFP fluorescence was occasionally observed in thin strata in the interior and even at the bottom of the biofilm (Figure 2B). The observation of fluorescent GFP at the bottom of the biofilm argues against the interpretation that these patterns are an artifact of incomplete IPTG penetration. click here In prior studies, the facile penetration

of IPTG throughout P. aeruginosa biofilms has been demonstrated [12, 14]. Figure 2 Spatial pattern of protein synthetic activity, as revealed by transient expression of an inducible GFP (green) in a P. aeruginosa biofilm grown in a drip-flow reactor. In this frozen section, the steel substratum was formerly at the bottom and the aerated nutrient medium at the top. Rhodamine B counterstaining (red) indicates the extent of

the biofilm. Table 1 Determination of mean biofilm thickness and mean dimension however of the zone in which GFP was expressed. Strain (plasmid) IPTG (mM) Biofilm*† Thickness (μm ± SD) GFP zone*† dimension (μm ± SD) Maximum† Fluorescence intensity (arbitrary ± SD) PAO1 (pAB1) 0 165 ± 100 none 24 ± 26 PAO1 (pAB1) 1 170 ± 78 66 ± 30 166 ± 61 PAO1 (pMF54) 1 120 ± 38 none 3 ± 1 *The thickness of the area of GFP expression as well as the overall thickness of the biofilm was measured 3 times. Measurement of Pseudomonas aeruginosa PAO1 carrying plasmid pAB1 containing an IPTG-inducible GFP with and without IPTG are compared with P. aeruginosa carrying plasmid pMF54 lacking GFP. †The uncertainties indicated are standard deviations. Transcriptional profiling of biofilms – nutritional and growth status The RNA was extracted from 3-day old P. aeruginosa drip-flow reactor grown biofilms and subjected to global transcriptional profiling. These microarray data have been deposited to Gene Expression Omnibus (GEO) accession GSE22164.

Breast Cancer Res Treat 1996, 38:67–73 PubMedCrossRef 2 Fukuoka

Breast Cancer Res Treat 1996, 38:67–73.PubMedCrossRef 2. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, check details Feyereislova A, Dong RP, Baselga J: Multi-institutional randomized phase II trial of Gefitinib for previously treated patients with advanced non-small cell lung cancer. J Clin Oncol 2003, 21:2237–2246.PubMedCrossRef 3. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D,

Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized AZD3965 clinical trial trial. JAMA 2003, 290:2149–2158.PubMedCrossRef 4. Lee DH, Park

K, Kim PLX-4720 in vivo JH, Lee JS, Shin SW, Kang JH, Ahn MJ, Ahn JS, Suh C, Kim SW: Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res 2010, 16:1307–1314.PubMedCrossRef 5. Huang H, Zhang Y, Zhao HY, Wang ZQ, Xu F, Xu GC, Zhang L, Guan ZZ: Analysis of the efficacy and safety of gefitinib in the treatment of recurrent advanced non-small cell lung cancer in an expanded access program (EAP). Zhonghua Zhong Liu Za Zhi 2009, 31:148–151.PubMed Ribose-5-phosphate isomerase 6. Niho S,

Kubota K, Goto K, Yoh K, Ohmatsu H, Kakinuma R, Saijo N, Nishiwaki Y: First-Line Single Agent Treatment With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer: A Phase II Study. J Clin Oncol 2006, 24:64–69.PubMedCrossRef 7. D’Addario G, Rauch D, Stupp R, Pless M, Stahel R, Mach N, Jost L, Widmer L, Tapia C, Bihl M, Mayer M, Ribi K, Lerch S, Bubendorf L, Betticher DC: Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03. Ann Oncol 2008, 19:739–745.PubMedCrossRef 8. Ebi N, Semba H, Tokunaga SJ, Takayama K, Wataya H, Kuraki T, Yamamoto H, Akamine SJI, Okamoto I, Nakanishi Y: A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer. J Thorac Oncol 2008, 3:1166–1171.PubMedCrossRef 9. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T, North-East Japan Study Group: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380–2388.PubMedCrossRef 10.

The initial phase II/dose-finding comparative

studies wer

The initial phase II/dose-finding comparative

studies were performed in between 2003 and 2004 in Australia GSK2118436 manufacturer [31] and Belgium and Germany [32]. The Australian study compared three doses of different formulations of find more HibMenCY-TT with licensed Hib-TT and MenC-CRM in infants at 2, 4, and 6 months of age [31]. The Belgium and German study compared three doses of different formulations of HibMenCY-TT with Hib-MenC-TT or DTap-HepB-IPV/Hib-TT and MenC-CRM [32] in infants at 2, 3, and 4 months, followed by a booster dose of HibMenCY-TT at 12–18 months. These phase II studies showed similar PRP and MenC seroprotection rates post primary [31, 32] and post fourth dose [32] and similar safety profiles after receipt of three or four doses of HibMenCY-TT compared with licensed control vaccines. Almost all infants (>97%) developed functional antibodies (rSBA titer ≥8) against MenY [31, 32]. The 2.5/5/5 μg formulation PF-02341066 concentration of HibMenCY-TT, was selected for further clinical development as it was the least reactogenic and was the only formulation that did not show any statistically significant

difference in the proportion of infants with rSBA titer ≥128 compared with MenC-CRM controls [32]. Table 1 Summary of HibMenCY-TT clinical trials Clinical trial Study years (country) Infant/toddler vaccinated cohort (n) Study description Control vaccines Concomitant vaccines Phase II dose finding studies Nolan et al. [31] 2003–2004 (Australia) 407/394 Immunogenicity and safety of 3 HibMenCY-TTa formulations at Resveratrol 2, 4, 6 months of age. Persistence to 11–14 months and response to PRP polysaccharide challenge Hib-TT or Hib-TT + MenC-CRM DTPa-HBV-IPV + PCV7 DTPa-HBV-IPV Habermehl et al. [32] 2003–2004 (Belgium and Germany) 388/221 Immunogenicity, persistence and safety of 3 HibMenCY-TTa formulations, 2, 3, 4 months, and 12–18 months of age

HibMenC or DTPa-HBV-IPV/Hib-TT + MenC DTPa-HBV-IPV – Phase II immunogenicity and safety Marchant et al. [33] 2004–2006 (US) 606/150 Immunogenicity and safety of HibMenCY-TTa, 2, 4, 6 months of age. Control group 3–5 year olds received MPSV4b Hib-TT DTPa-HBV-IPV + PCV7 Marshall et al. [34] 2005–2007 (US) –/498 Immunogenicity and safety of HibMenCY-TTa at 12–15 months of age (previously received three doses at 2, 4, 6 months in study above [33]) and persistence 1 year after the fourth dose Hib-TT (12–15 months) PCV7 Marshall et al. [35] 2005–2006 (US) 606/366 Immune response of concomitant antigens given with HibMenCY-TTa at 2, 4, 6 and 12–15 months of age Hib-TT DTPa-HBV-IPV + PCV7 Nolan et al. [36] 2005–2007 (Australia) 1,103/1,037 Immunogenicity and safety of HibMenCY-TTa at 2, 4, 6, and 12–15 months of age Hib-TT + MenC-CRM (HibMenCY-TT at 12–15 months) or Hib-TT (Hib-OMP at 12–15 months) DTPa-HBV-IPV + PCV7 (MMR + Varivax) DTPa-HBV-IPV + PCV7 (MMR + Varivax) Phase III pivotal Bryant et al.

Bacterial transport proteins are classified according to their me

Bacterial transport proteins are classified according to their mechanism and include primary active transporters, secondary transporters, channels

and pores [57]. In the present study, the intracellular concentration of 16 transport-associated proteins (five porins and 11 substrate-specific transporters) was significantly altered by a pH increase to 8.2 (Table 1). The increased intracellular concentration of TRAP transporters and increased SIS3 concentration of ABC transporter binding proteins could be considered to be energy conserving as TRAP transporters rely on proton-motive force instead of ATP hydrolysis (ABC transporters) to drive the uptake of solutes from the environment. In contrast to our results, the production of TRAP transporter binding proteins was suppressed 10-fold in planktonic cells cultured at pH 7.8 [27]. The authors explained that the decreased abundance of TRAP binding proteins in planktonic cells may be due to a reduced proton gradient [27]. However, bacterial cells growing within a biofilm structure may be more protected from pH fluctuation and the loss of protons to the environment. This may explain

the increased production of TRAP transporters in biofilms was observed. The virulence of F. nucleatum is largely due to the adhesive properties that allow the bacterium to interact with perio-dontopathogens and host cells during the onset this website of periodontal disease. Two identified adhesins, RadD and FomA, are among the outer membrane proteins that are responsible for interspecies and host cell interactions [58–60]. The intracellular

concentration of the adhesin FomA did not appear to be altered by planktonic F. nucleatum cells when cultured at pH 7.8 [27]. In the present study, however, the abundance levels of four FomA isoforms, with isoelectric points varying between 7 and 9, increased significantly in biofilm cells (Table 1). A preliminary study in the laboratory indicated that two FomA isoforms (spots 41 and 42, Figure 1 and Table 1) could be phosphorylated (data not shown) and further studies are required to determine the roles of these isofoms in biofilm tuclazepam cells. The protein is thought to be associated with mature plaque biofilm development as it facilitates the coaggregation between F. nucleatum and other bacteria such as P. gingivalis[60, 61]. A more recent study demonstrated that in a mouse periodontitis model a bacterial suspension of P. gingivalis and F. nucleatum neutralised with anti-FomA antibody showed a significant reduction in abscess formation and gingival swelling [60]. Our GSK690693 manufacturer results support the suggestion that FomA is a potential vaccine target for periodontal disease. As mentioned previously, significant changes in cell morphology were associated with F. nucleatum biofilm formation [18]. Biofilm cells cultured at pH 8.2 presented with a significant increase in length.

Infect Immun 1999,67(3):1213–1219 PubMed 69 Hancock LE, Gilmore

Infect Immun 1999,67(3):1213–1219.PubMed 69. Hancock LE, Gilmore MS: The capsular Poziotinib in vivo polysaccharide of Enterococcus faecalis and its relationship to other polysaccharides in the cell wall. Proc Natl Acad Sci U S A 2002,99(3):1574–1579.PubMed 70. Xu Y, Singh KV, Qin X, Murray BE, Weinstock GM: Analysis of a gene cluster of Enterococcus faecalis involved in polysaccharide biosynthesis. Infect Immun 2000,68(2):815–823.PubMed 71. Sillanpaa J, Nallapareddy

SR, Singh KV, Prakash VP, Fothergill TAM Receptor inhibitor T, Ton-That H, Murray BE: Characterization of the ebp(fm) pilus-encoding operon of Enterococcus faecium and its role in biofilm formation and virulence in a murine model of urinary tract infection. Virulence 2010,1(4):236–246.PubMed 72. Hendrickx AP, van Luit-Asbroek M, Schapendonk CM, van Wamel WJ, Braat JC, Wijnands LM, Bonten MJ, Willems RJ: SgrA, a nidogen-binding LPXTG surface adhesin implicated in biofilm formation, and EcbA, a collagen binding MSCRAMM, are two novel adhesins of hospital-acquired Enterococcus faecium. Infect Immun 2009,77(11):5097–5106.PubMed 73. Coque TM, Tomayko JF, Ricke SC, Okhyusen PC, Murray BE: Vancomycin-resistant enterococci from nosocomial, community, and animal sources in the United States. Antimicrob

Agents Chemother 1996,40(11):2605–2609.PubMed 74. Wilson K: Preparation

of Genomic DNA from Bacteria. Green Publishing Associates, Brooklyn, N.Y.; 1994. 75. Delcher AL, Bratke KA, Powers EC, Salzberg SL: Identifying bacterial genes Adriamycin and endosymbiont DNA with Glimmer. Bioinformatics 2007,23(6):673–679.PubMed 76. Besemer J, Borodovsky M: Heuristic approach to deriving models for gene finding. Nucleic Acids Res 1999,27(19):3911–3920.PubMed 77. Lowe TM, Eddy SR: tRNAscan-SE: a program for improved detection of transfer RNA genes in genomic sequence. Glycogen branching enzyme Nucleic Acids Res 1997,25(5):955–964.PubMed 78. Lagesen K, Hallin P, Rodland EA, Staerfeldt HH, Rognes T, Ussery DW: RNAmmer: consistent and rapid annotation of ribosomal RNA genes. Nucleic Acids Res 2007,35(9):3100–3108.PubMed 79. Griffiths-Jones S, Moxon S, Marshall M, Khanna A, Eddy SR, Bateman A: Rfam: annotating non-coding RNAs in complete genomes. Nucleic Acids Res 2005,33((Database issue)):D121–124.PubMed 80. Finn RD, Mistry J, Tate J, Coggill P, Heger A, Pollington JE, Gavin OL, Gunasekaran P, Ceric G, Forslund K, et al.: The Pfam protein families database. Nucleic Acids Res 2010,38((Database issue)):D211–222.PubMed 81. Tatusov RL, Galperin MY, Natale DA, Koonin EV: The COG database: a tool for genome-scale analysis of protein functions and evolution. Nucleic Acids Res 2000,28(1):33–36.PubMed 82.

PubMedCrossRef 9 Lozupone CA, Stombaugh JI, Gordon JI, Jansson J

PubMedCrossRef 9. Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R: Diversity, stability and resilience of the human gut microbiota. Nature 2012,489(7415):220–230.PubMedCrossRef 10. Nelson JS: Fishes of the world. Hoboken, New Yersey: John Wiley & Sons; 2006. 11. Sullam KE, Essinger SD, Lozupone CA, O’Connor MP, Rosen GL, Knight ROB, Kilham SS, Russell JA: Environmental and ecological factors that shape the gut bacterial communities of fish: a meta-analysis. Mol Ecol 2012,21(13):3363–3378.PubMedCrossRef Inhibitor Library cell line 12. Star

B, Nederbragt AJ, Jentoft S, Grimholt U, Malmstrom M, Gregers TF, Rounge TB, Paulsen J, Solbakken MH, Sharma A, et al.: The genome sequence of Atlantic cod reveals a unique immune system. Nature 2011,477(7363):207–210.PubMedCrossRef 13. Star B, Jentoft S: Why does the immune system of Atlantic cod lack MHC II? Bioessays 2012,34(8):648–651.PubMedCrossRef 14. Geraylou Z, Souffreau C, Rurangwa E, D’Hondt S, Callewaert L, Courtin CM, Delcour JA, Buyse J, Ollevier F: Effects of arabinoxylan-oligosaccharides (AXOS) on juvenile Siberian sturgeon (Acipenser baerii) performance, immune responses and gastrointestinal microbial community. Fish Shellfish Immun 2012,33(4):718–724.CrossRef 15. Wu S, Wang G, Angert ER,

Wang W, Li W, Zou H: Composition, diversity, and MK 8931 ic50 origin of the bacterial community in Grass carp intestine. Plos One 2012,7(2):e30440.PubMedCrossRef 16. van Kessel M, Dutilh B, Neveling K, Kwint M, Veltman J, Flik G, Jetten M, Klaren P, Op den Camp H: Pyrosequencing of 16S rRNA gene amplicons to study the microbiota in the gastrointestinal tract of carp ( Cyprinus carpio L.). AMB Express 2011,1(1):41.PubMedCrossRef 17. Roeselers G, Mittge EK, Stephens WZ, Parichy DM, Cavanaugh CM, L-gulonolactone oxidase Guillemin K, Rawls JF: Evidence for a core gut microbiota in the zebrafish. ISME J 2011,5(10):1595–1608.PubMedCrossRef

18. Ringø E, Sperstad S, Myklebust R, Refstie S, Krogdahl A: Characterisation of the microbiota associated with intestine of Atlantic cod ( Gadus morhua L.) – The effect of fish meal, standard soybean meal and a bioprocessed soybean meal. Aquaculture 2006,261(3):829–841.CrossRef 19. Fjellheim AJ, Playfoot KJ, Skjermo J, Vadstein O: Vibrionaceae dominates the microflora antagonistic towards Listonella anguillarum in the intestine of cultured Atlantic cod ( Gadus morhua L.) larvae. Aquaculture 2007,269(1–4):98–106.CrossRef 20. Brunvold L, Sandaa R-A, Mikkelsen H, Welde E, Bleie H, Bergh O: Characterisation of bacterial communities associated with early stages of intensively reared cod (Gadus morhua) using Denaturing Gradient Gel Electrophoresis (DGGE). Aquaculture 2007,272(1–4):319–327.CrossRef 21. Reid HI, Treasurer JW, Adam B, Birkbeck TH: Analysis of bacterial populations in the gut of developing cod LY3009104 ic50 larvae and identification of Vibrio logei, Vibrio anguillarum and Vibrio splendidus as pathogens of cod larvae. Aquaculture 2009,288(1–2):36–43.CrossRef 22.